135 related articles for article (PubMed ID: 36929429)
21. Del(1p32): prime time in (ultra) high-risk myeloma.
Khot A
Blood; 2023 Mar; 141(11):1241-1243. PubMed ID: 36929439
[No Abstract] [Full Text] [Related]
22. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
Chan NC; Chan NP
Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
[TBL] [Abstract][Full Text] [Related]
23. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
26. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah V; Sherborne AL; Walker BA; Johnson DC; Boyle EM; Ellis S; Begum DB; Proszek PZ; Jones JR; Pawlyn C; Savola S; Jenner MW; Drayson MT; Owen RG; Houlston RS; Cairns DA; Gregory WM; Cook G; Davies FE; Jackson GH; Morgan GJ; Kaiser MF
Leukemia; 2018 Jan; 32(1):102-110. PubMed ID: 28584253
[TBL] [Abstract][Full Text] [Related]
27. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
28. [Cytogenetic abnormalities in high-risk multiple myeloma].
Ishida T
Nihon Rinsho; 2015 Jan; 73(1):28-32. PubMed ID: 25626299
[TBL] [Abstract][Full Text] [Related]
29. Making a case for del(1p) as a high-risk abnormality in multiple myeloma.
Schmidt TM
Cancer; 2023 Aug; 129(16):2450-2452. PubMed ID: 37282718
[No Abstract] [Full Text] [Related]
30. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
Hematology; 2023 Dec; 28(1):2161222. PubMed ID: 36607148
[TBL] [Abstract][Full Text] [Related]
32. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
34. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
[TBL] [Abstract][Full Text] [Related]
35. [Detection of complex chromosomal aberrations in patients with multiple myeloma using multiplex fluorescence in situ hybridization].
Jiang YQ; Chen LJ; Zhu Y; Qiu HR; Wang R; Xu JR; Lu H; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):441-4. PubMed ID: 20677154
[TBL] [Abstract][Full Text] [Related]
36. Natural history of multiple myeloma with de novo del(17p).
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma.
Tapper W; Chiecchio L; Dagrada GP; Konn ZJ; Stockley DM; Szubert AJ; Gregory WM; Bell SE; Jackson GH; Child JA; Morgan GJ; Ross FM
J Clin Oncol; 2011 Jan; 29(2):e37-9; author reply e40-1. PubMed ID: 21135272
[No Abstract] [Full Text] [Related]
38. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
39. [Genetic markers as prognostic factors in multiple myeloma].
Conte L G; Braggio E; Figueroa G; Fonseca R
Rev Med Chil; 2009 Apr; 137(4):552-8. PubMed ID: 19623423
[TBL] [Abstract][Full Text] [Related]
40. Risk Stratification in Multiple Myeloma.
Ooi MG; de Mel S; Chng WJ
Curr Hematol Malig Rep; 2016 Apr; 11(2):137-47. PubMed ID: 26883334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]